Carlisle Companies Incorporated (NYSE:CSL) today announced the signing of a definitive agreement to acquire Providien LLC, a leading provider of comprehensive manufacturing solutions for global medical device OEMs, including: thermoforming, medical device contract manufacturing, precision machining & metals, and medical injection molding. The purchase of Providien is consistent with Carlisle’s Vision 2025 strategy to build scale with synergistic acquisitions to drive to $15 of earnings per share. Providien will become part of the Carlisle Interconnect Technologies (CIT) operating segment. The transaction is subject to customary closing conditions and is expected to close in the fourth quarter of 2019.
Based in San Diego, California, and with over 1,000 employees, Providien has additional facilities in California and Tijuana, Mexico.
Chris Koch, President and Chief Executive Officer said, βThe acquisition of Providien fits our Medical Technologies platform expansion and vertical integration strategy, driven by aging populations and increased preference for minimally invasive surgical procedures. Providien adds new products for medical markets, including: Robotics, Drug Delivery, Oncology, and Kyphoplasty, currently not served by CIT’s product portfolio.
Providien also establishes a Medical new product development and manufacturing footprint in the U.S. for CIT. The combined CIT Medical Technologies platform, which includes redgroup, MicroConnex, LHi Technology and Providien uniquely positions Carlisle to be a one-stop shop to key medical device customers. We are very pleased to welcome the Providien team to Carlisle.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: BusinessWire